We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

International Melanoma Algorithm Training Study - IMATS

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: August 26, 2009
Last Update Posted: August 11, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
SciBase AB
This is an international, multicenter, prospective, non controlled, non randomized, clinical study to collect electrical impedance data of potentially malignant pigmented nevi and histological diagnoses (International Melanoma Algorithm Training Study [IMATS]). The study objective is to collect data for training and optimization of an algorithm that can classify skin lesions using electrical impedance, i.e., to identify malignant melanomas.

Condition Intervention
Malignant Melanoma Device: SciBase III Electrical Impedance Spectrometer

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: An International, Multicenter, Prospective, Non-controlled, Non-randomised, Clinical Study to Collect Impedance Data of Potentially Malignant Pigmented Nevi and Histological Diagnoses

Resource links provided by NLM:

Further study details as provided by SciBase AB:

Primary Outcome Measures:
  • Outcome measure not applicable. This is an algorithm training study. [ Time Frame: Q1 2010 ]

Estimated Enrollment: 1800
Study Start Date: December 2005
Study Completion Date: July 2010
Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)
Intervention Details:
    Device: SciBase III Electrical Impedance Spectrometer
    Following enrollment, patients will undergo measurements with SciBase III Electrical Impedance Spectrometer. Electrical impedance of the skin will be measured with a microinvasive spiked probe.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Men and women of any ethnic group
  • Lesion located on normal healthy skin
  • Maximum number of eight lesions per patient
  • etc.

Exclusion Criteria:

  • Lesion under finger and toe nails
  • Lesion located on eczema, psoriasis areas or similar
  • Lesion located on scars
  • etc.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00966173

Sahlgrenska University Hospital, Dpt. of Dermatology
Gothenburg, Sweden, 41345
Sponsors and Collaborators
SciBase AB
  More Information

Responsible Party: Anders Lundqvist, CEO, SciBase AB
ClinicalTrials.gov Identifier: NCT00966173     History of Changes
Other Study ID Numbers: 6001
First Submitted: August 25, 2009
First Posted: August 26, 2009
Last Update Posted: August 11, 2010
Last Verified: August 2010

Additional relevant MeSH terms:
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas